NEW YORK–(BUSINESS WIRE)–Kroll Bond Rating Agency (KBRA) announces the preliminary ratings to two note classes of Drug Royalty III LP 1, a drug royalty securitization. This transaction is backed by royalty revenues from 12 royalty streams on 11 pharmaceutical products and/or technologies. The Series 2017-1 notes will be the Issuer’s second series within the master trust, and will be serviced by DRI Capital Inc. (“DRI”, or the “Company”). The first series under the master trust was the 2016-1
